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issues for patients with chronic mesenteric ischemia
(CMI) include the basic questions of treatment type
(open vs endovascular revascularization), bypass configu-
ration (antegrade vs retrograde), conduit (autogenous 
vs prosthetic), and the number of vessels to be revascu-
larized (1 vs 2 vs 3). Furthermore, the relative infre-
quency of these procedures severely limits the overall
surgeon/institution experience outside of these select
centers. It is uncertain whether the outcomes are compa-
rable at the community level and whether the decision
algorithms based on the outcomes in select centers are
appropriate in this setting. Indeed, repair of intact thora-
coabdominal aortic aneurysms (TAAs) is usually recom-
mended for aneurysms 6 cm or more in diameter on the
basis of the presumed death caused by rupture of unre-
paired aneurysms and an operative mortality rate for
elective repair.1,2 An increased operative mortality rate
would favor delaying repair until the maximal diameter
and rupture risk are greater or referral to a center where
lower mortality rates could be achieved. This study 
was designed to determine the outcome and identify 
predictors of death for three uncommon, complex vascu-
lar surgical procedures (TAA, renal artery bypass RAB,
and revascularization for CMI) in the United States 
during 1993 to 1997 with the Nationwide Inpatient
Sample (NIS).
The appropriate management of most vascular surgi-
cal problems requires a clear understanding of the natural
history of the disease process untreated and the outcome
after surgical or endovascular therapy. Unfortunately, the
outcome after many infrequently performed, complex
vascular surgical procedures remains poorly defined. The
published reports in which the outcome after these pro-
cedures is documented are composed of relatively small
case series from surgeons and institutions with special
expertise and have been reported predominantly from
academic medical centers. In addition, the management
of these problems often varies significantly among these
centers, thereby limiting the compilation of results and
leaving many issues unresolved. Indeed, the unresolved
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Objectives: The purpose of this study was to determine outcome and identify predictors of death after thoracoabdominal
aortic aneurysm (TAA) repair, renal artery bypass (RAB), and revascularization for chronic mesenteric ischemia (CMI).
Patients and Methods: In this retrospective analysis,
data were obtained from the Nationwide Inpatient Sample, a 20% all-payer stratified sample of hospitals in the United
States during 1993 to 1997. Patients were identified by the presence of a diagnostic or procedure code from the
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The main outcomes we
examined were death, ICD-9-CM–based complications, length of stay, hospital charges, and disposition. A multivariate
model was constructed to predict death.
Results: A total of 2934 patients were identified (TAA, 540; RAB, 2058; CMI, 336) in the database. The mean age was
comparable (TAA, 69 ± 9 years; RAB, 66 ± 12 years; CMI, 66 ± 11 years), but the breakdown between the sexes var-
ied by procedure (male: TAA, 53%; RAB, 55%; CMI, 24%). The mortality rate (TAA, 20.3%; RAB, 7.1%; CMI, 14.7%),
complication rate (TAA, 62.2%; RAB, 37.4%; CMI, 44.6%), and the percentage of patients discharged to another insti-
tution (TAA, 21.2%; RAB, 9.3%; CMI, 12.0%) were clinically significant for all procedures. The mortality rate for RAB
was greater when performed concomitant with an aortic reconstruction (4.4% vs 8.3%). All three procedures were
resource intensive as reflected by the median length of stay (TAA, 14 days; RAB, 9 days; CMI, 14 days) and median hos-
pital charges (TAA, $64,493; RAB, $36,830; CMI, $47,390). The multivariate model identified several variables for
each procedure that had an impact on the predicted mortality rate (TAA, 14%-76%; RAB, < 1%-46%; CMI, < 2%-87%).
Conclusions: The operative mortality rates across the United States for patients undergoing TAA repair and RAB are
greater than commonly reported in the literature and mandate reexamining the treatment strategies for these complex
vascular problems. (J Vasc Surg 2001;34:54-61.)
METHODS
Data were obtained for the calendar years 1993 to
1997 from the NIS,3-5 which is part of the Healthcare
Cost and Utilization Project.6 The NIS is the largest all-
payer inpatient care database and contains data from more
than 6 million annual discharges from more than 900 hos-
pitals in 19 states. The database approximates a 20% strat-
ified sample of community hospitals in the United States
with the stratification criteria including geographic region,
ownership, location, teaching status, and bed size. The
discharge abstract includes the diagnostic and procedure
codes (1-35 codes each) of the International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM),7 admission and discharge status, patient
demographics, payment source, total hospital charges,
length of stay, and hospital characteristics.
A dataset of patients undergoing TAA repair, RAB,
and revascularization for CMI was constructed with com-
binations of the ICD-9-CM diagnostic and procedure
codes. Patients undergoing TAA repair were identified by
the combination of a diagnostic code 441.7 (thoracoab-
dominal aneurysm, without mention of rupture) and pro-
cedure codes 38.45 and 38.44 (38.45: resection of
abdominal aorta with replacement; 38.44: resection of
thoracic aorta with replacement). Patients undergoing
RAB were identified by the presence of the procedure
code 39.24 (aorta-renal bypass). Patients undergoing
revascularization for CMI were identified by the combina-
tion of the diagnostic code 557.1 (chronic vascular insuf-
ficiency of intestine) and the procedure code 39.26 (other
intra-abdominal shunt or bypass).
The dataset was analyzed with patient demographics
and hospital characteristics. The race classification was
simplified in the analysis to include only white, black, or
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other. However, it was unavailable among the discharge
data from every state. The hospital characteristics of loca-
tion, teaching status, and size were obtained from the
stratification criteria.6 Outcome measures included death,
postoperative complications, length of stay, discharge dis-
position, and hospital charges. Death was defined as in-
hospital death, and the complications were identified by
the presence of ICD-9-CM complication codes. These
included the complications of medical care (996-999) and
cardiac complication (997.1).8 The discharge disposition
among those discharged was simplified in the analysis to
either home (routine, home health, against medical
advice) or another institution (all others). Patients who
either died in the hospital or were discharged to another
institution were arbitrarily considered as having a “bad
outcome.”3 The charges analyzed reflect only those for
the inpatient hospitalization during which the procedure
was performed. All charges were converted to 1997 dol-
lars with the use of a 4% annual rate of inflation.
Death was analyzed with demographics, comorbidi-
ties, the calendar year, and hospital characteristics. The
comorbidities were identified by the ICD-9-CM diagnos-
tic codes for diabetes mellitus (250.0-250.9), hyperten-
sion (401.0-405.9), preoperative renal insufficiency
(584.0-586.0, 403.0-403.9), chronic obstructive pul-
monary disease (490.0-496.0), ischemic heart disease
(410.0-414.9), cerebral vascular occlusive disease (430.0-
438.0), and peripheral arterial occlusive disease (440.0-
440.9, 443.0-443.9).3,9 The number of secondary
diagnostic codes were classified into the groups 0 to 1, 2
to 3, and more than 3 after excluding the complication
codes (996-999).3,9 Death in the RAB group was also
analyzed according to whether the patients underwent a
concomitant aortic reconstruction. The concomitant aor-
Table I. Summary of demographics and hospital characteristics 
TAA RAB CMI
Patient characteristics
Age (y) 69.3 ± 8.8 66.3 ± 11.4 65.5 ± 11.1
< 50 18 (3.3%) 157 (7.6%) 27 (8.0%)
50-59 36 (6.7%) 264 (12.8%) 73 (21.7%)
60-69 191 (35.4%) 727 (35.3%) 95 (28.3%)
70-79 252 (46.7%) 795 (38.6%) 112 (33.3%)
> 79 43 (8.0%) 115 (5.6%) 29 (8.6%)
Male 284 (52.6%) 1124 (54.6%) 80 (24.0%)
Female 256 (47.4%) 934 (45.4%) 256 (76.2%)
White 406 (87.7%) 1531 (93.4%) 234 (90.7%)
African American 39 (8.4%) 65 (4.0%) 14 (5.4%)
Other 18 (3.9%) 44 (2.7%) 10 (3.9%)
Hospital characteristics
Small 17 (3.2%) 120 (5.9%) 30 (9.0%)
Medium 120 (22.2%) 527 (25.7%) 95 (28.4%)
Large 403 (74.6%) 1405 (68.5%) 210 (62.7%)
Nonteaching 202 (37.4%) 1026 (50.0%) 155 (46.6%)
Teaching 338 (62.6%) 1026 (50.0%) 180 (53.7%)
Rural 2 (0.37%) 81 (4.0%) 22 (6.6%)
Urban 538 (99.6%) 1971 (96.1%) 313 (93.4%)
tic reconstructions were identified by the presence of any
of the following procedure codes: 38.44, 38.34, 38.36,
38.40, 38.46, 38.60, 38.64, 38.66, 38.84, 39.24, 39.25,
39.26, 39.52, 39.56, 39.57.3,9 A multivariate model was
constructed for each of the three procedures to predict
death after correcting for the calendar year and the
patient/hospital variables previously listed.
All data are presented as mean ± SD unless otherwise
specified. The outcomes after the three procedures were
compared with χ2 analysis for the categoric variables and
analysis of variance for the continuous variables. Stepwise
model building was implemented with CATMOD proce-
dure and backward model selection in SAS (SAS Institute,
Cary, NC) to fit a model that predicted death.10,11 A P
value less than .05 was accepted as significant. All data
analyses were performed with SAS version 7.0 (SAS
Institute) running under Microsoft Windows NT
(Microsoft, Redmond, Wash) on an Intel Pentium class
personal computer (Intel Corp, Santa Clara, Calif).
RESULTS
Thoracoabdominal aortic aneurysm repair. A total
of 540 discharge abstracts during which patients under-
went repair of TAAs were identified. The mean patient age
was 69.3 ± 8.8 years, and patients aged between 70 and 79
years comprised the largest group (Table I). Slightly more
than half of the patients were male and most were white.
Most of the procedures were performed at large, teaching,
and urban institutions. The inpatient mortality rate was
20.3%, the overall complication rate was 62.2%, and 58.5%
of the patients were discharged home. This corresponded
to a bad outcome rate of 41.5% (Table II). The median
hospital length of stay was 14 days, whereas the median
hospital charges were $64,493.
Outcome after TAA repair was significantly affected by
demographics, comorbidities and hospital characteristics
in the univariate analysis (Appendices I and II, online
only). The percentage of patients with bad outcome was
greater for older patients (younger than 50, 27.8%; older
than 79, 67.4%) and those whose race was classified as
other (white, 40.7%; African American, 35.9%; other,
77.8%), whereas the percentage of patients discharged to
another institution (< 50, 5.6%; > 79, 41.9%) increased
with age. Death was increased for patients with cerebral
vascular occlusive disease (35.4% vs 18.8%) and those with
renal insufficiency (41.3% vs 16.0%). The multivariate
model found that renal insufficiency, cerebral vascular
occlusive disease, and diabetes were significant predictors
of death (Table III). The predicted mortality rate ranged
from 14% (no significant predictors) to 76% (renal insuffi-
ciency, cerebral vascular occlusive disease, diabetes) among
the eight combinations of significant variables.
Renal artery bypass. A total of 2058 discharge
abstracts during which patients underwent RAB were
identified. The mean patient age was 66.3 ± 11.4 years,
and patients aged between 70 and 79 years comprised the
largest group (Table I). Most patients were male and
white, whereas most of the procedures were performed at
large, urban institutions, although equal numbers were
performed at institutions classified as teaching and non-
teaching. The inpatient mortality rate was 7.1%, the over-
all complication rate was 37.4%, and the overwhelming
majority of patients were discharged home for a corre-
sponding bad outcome rate of 16.4% (Table II). The mor-
tality rate among those patients undergoing bypass alone
(33%) was 4.4%, whereas that for patients undergoing
bypass and concomitant aortic reconstruction (67%) was
8.3%. The median length of stay was 9 days, whereas the
median hospital charges were $36,830.
Outcome after RAB varied significantly by demo-
graphics, comorbidities, and hospital characteristics in the
univariate analysis (Appendices II and III, online only).
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Table II. Summary of outcome 
TAA RAB CMI
In-hospital death 20.3% 7.1% 14.7%
Discharge institution 21.2% 9.3% 12.0%
Discharge home 58.5% 83.6% 73.4%
Any complication 62.2% 37.4% 44.6%
Cardiac complication 18.7% 8.0% 9.8%
Bad outcome 41.5% 16.4% 26.7%
Mean length of stay (d) 19.4 ± 19.0 13.0 ± 11.8 18.3 ± 16.1
Median length of stay (d) 14 9 14
Mean hospital charges ($) 94,659 ± 85,747 51,695 ± 59,128 76,828 ± 92,824
Median hospital charges ($) 64,493 36,830 47,390
Table III. Predicted mortality rates after TAA repair
Renal Cerebral Mortality
insufficiency vascular disease Diabetes rate
No No No 0.141
No Yes No 0.261
No No Yes 0.279
Yes No No 0.388
No Yes Yes 0.455
Yes Yes No 0.579
Yes No Yes 0.600
Yes Yes Yes 0.764
The percentage of patients discharged to another institu-
tion (11.0% vs 7.9%) and the percentage with a bad out-
come (18.7% vs 4.4%) were both greater among women.
All of the outcome measures varied by age, and the per-
centage of adverse outcomes trended inversely with age
for most of the measures. Notably, the mortality rate
(14.8% vs 1.3%), percentage of patients discharged to
another institution (21.8% vs 2.6%), and bad outcome rate
(36.5% vs 3.8%) were markedly higher for the oldest
group relative to the youngest (older than 79 vs younger
than 50). The mortality rate was somewhat greater for
patients with multiple comorbidities (0-2, 5.6%; 3-4,
3.4%; > 4, 7.8%) and was dramatically worse for patients
with renal insufficiency (19.8% vs 6.6%). Both the pres-
ence of hypertension (5.4% vs 9.0%) and the presence of
peripheral arterial occlusive disease (5.2% vs 13.8%) were
associated with a decreased mortality rate. Both the per-
centage of patients discharged to another institution
(small, 10.1%; medium, 12.4%; large, 8.2%) and those
with bad outcome (small, 12.6%; medium, 20.0%; large,
15.4%) varied with the hospital size. The multivariate
model found that renal insufficiency, peripheral arterial
occlusive disease, and age were significant predictors of
death (Table IV). The predicted mortality rates ranged
from less than 1% (peripheral arterial occlusive disease, 
< 50 years) to 46% (renal insufficiency, > 79 years) among
the 20 combinations of significant variables.
Revascularization for chronic mesenteric ischemia.
A total of 336 discharge abstracts during which patients
underwent mesenteric revascularization for CMI were
identified. The mean patient age was 65.5 ± 11.1 years,
and those aged between 70 and 79 years comprised the
largest group (Table I). Most of the patients were female
and white, whereas most of the revascularizations were
performed at large, teaching, and urban institutions. The
inpatient mortality rate was 14.7%, and 44.6% of the
patients experienced some type of complication, although
73.4% were discharged home (Table II). This corre-
sponded to an overall bad outcome rate of 26.7%. The
median length of stay was 14 days, and the median hospi-
tal charges were $47,390.
Outcome after revascularization for CMI was found to
vary significantly by demographics, comorbidities and
hospital characteristics in the univariate analysis
(Appendices II and IV, online only). A larger percentage
of women (male, 5.0% vs female, 14.2%) and older
patients (younger than 50, 0.0% vs older than 79, 44.8%)
were discharged to another institution, and the bad out-
come rate was worse for the older patients (younger than
50 years, 7.0% vs older than 79 years, 58.6%). Death was
dramatically higher for patients with renal insufficiency
(48.0% vs 12.0%) and those with multiple comorbidities
(0-2, 2.3%; 3-4, 3.3%; > 4, 20.3%). The mortality rate
(small, 30.0%; medium, 12.6%; large, 13.5%) and the per-
centage of patients discharged to another institution
(small, 3.3%; medium, 19.0%; large, 10.1%) varied with
the size of the institution. The multivariate model con-
structed to predict death found that renal insufficiency,
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ischemic heart disease, the number of comorbidities, and
hospital size all had significant effects (Table V). The pre-
dicted mortality rate ranged from less than 2% (0-2
comorbidities, medium hospital) to 87% (renal insuffi-
ciency, ischemic heart disease, > 4 comorbidities, small
hospital) among the 36 combinations of significant vari-
ables.
DISCUSSION
The current study documents the outcome in the
United States for TAA repair, RAB, and revascularization
for CMI. However, the data must be interpreted with
some caution and the clinical conclusions tempered. The
NIS is an administrative database designed for billing pur-
poses that was adapted to answer several clinical questions.
The data contain a finite number of clinical variables and
lack several important ones including the indications for
the various procedures. Furthermore, the accuracy of the
clinical data is contingent on the abstracters and coders. It
is notable that a recent survey of Medicare claims reported
a 25% error rate for the primary diagnostic and procedure
code.12 The abstracting process likely undercodes or
underreports complications and does not adequately
account for the patients’ severity of disease or comorbidi-
ties. In contrast, the mortality data are likely accurate
because they represent a discrete end point. However, the
in-hospital mortality rate was used for the current analysis
rather than the more traditional 30-day mortality rate. It
is unlikely that these values are significantly different for
the three procedures analyzed because patients who die in
the early postoperative period usually have complicated
immediate postoperative courses and are rarely discharged
home. Despite the limitations of the database, the analysis
Table IV. Predicted mortality rates after RAB
Peripheral 
Renal arterial occlusive Age Mortality 
insufficiency disease group (y) rate
No Yes < 50 0.006
No Yes 50-59 0.012
No No < 50 0.016
Yes Yes < 50 0.027
No Yes 60-69 0.030
No No 50-59 0.032
No Yes 70-79 0.045
Yes Yes 50-59 0.053
No Yes > 79 0.063
Yes No < 50 0.070
No No 60-69 0.077
No No 70-79 0.115
Yes Yes 60-69 0.122
Yes No 50-59 0.133
No No > 79 0.156
Yes Yes 70-79 0.177
Yes Yes > 79 0.235
Yes No 60-69 0.277
Yes No 70-79 0.372
Yes No > 79 0.458
does provide a useful global picture or “broad brush
stroke” of the national practice.
The incidence of adverse outcomes after TAA repair is
sobering and mandates reexamination of the current treat-
ment algorithm. The in-hospital morality rate of 20.3%
was essentially double the values reported from the larger
institutional series.13-16 It should be noted that the oper-
ative mortality rate reflects all four classifications of TAAs
(Crawford I-IV) and almost certainly included some emer-
gency repairs and contained ruptures or frank ruptures
despite our selection criteria that attempted to exclude the
latter. The previously reported mortality rates vary some-
what by aneurysm type with the highest values reported
for the types II and III17 and are significantly greater for
emergency repairs with values approaching 50%.17
Regardless, it seems likely that a patient with a 6-cm TAA
may not benefit significantly from repair if the operative
mortality rate is 20%. In such a case, either operative inter-
vention should be delayed until the rupture risk offsets
this mortality rate, or strategies should be implemented to
reduce it, such as concentrating the repairs at select cen-
ters of excellence or improving the patient selection.
Unfortunately, the predictive model identified only cere-
bral vascular occlusive disease, renal insufficiency, and dia-
betes as significant variables for the operative mortality
rate. Admittedly, the ICD-9-CM–based diagnostic codes
for the comorbidities are somewhat nonspecific, and it
would be difficult to withhold operative repair from a
patient just because they were diabetic. However, the pres-
ence of renal insufficiency should be factored into the
operative decision algorithm because it has been shown to
be a significant predictor of death in multiple series of
infrarenal abdominal aortic aneurysm repairs.3,18,19
Finally, the justifications for TAA repair have focused pri-
marily on the balance between the rupture risk and the
operative mortality rate. However, the risk/benefit
approach with these outcomes alone may be too restrictive
from a patient perspective. Other end points such as qual-
ity of life, ability to live independently, and ambulatory
status may be equally important and should be openly dis-
cussed with operative candidates and factored into the
decision algorithm. Approximately 21% of the patients
were discharged to another institution after TAA repair,
and the rate exceeded 42% for those patients older than 79
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Table V. Predicted mortality rates after revascularization for CMI
Renal insufficiency Ischemic heart disease Comorbidities Hospital size Mortality rate
No No 0-2 Medium 0.016
No No 3-4 Medium 0.017
No No 0-2 Large 0.019
No No 3-4 Large 0.020
No Yes 0-2 Medium 0.033
No Yes 3-4 Medium 0.036
No Yes 0-2 Large 0.038
No Yes 3-4 Large 0.041
No No 0-2 Small 0.059
No No 3-4 Small 0.063
Yes No 0-2 Medium 0.104
No No > 4 Medium 0.106
Yes No 3-4 Medium 0.111
No Yes 0-2 Small 0.117
Yes No 0-2 Large 0.119
No No > 4 Large 0.122
No Yes 3-4 Small 0.124
Yes No 3-4 Large 0.127
Yes Yes 0-2 Medium 0.197
No Yes > 4 Medium 0.201
Yes Yes 3-4 Medium 0.208
Yes Yes 0-2 Large 0.222
No Yes > 4 Large 0.226
Yes Yes 3-4 Large 0.234
Yes No 0-2 Small 0.308
No No > 4 Small 0.313
Yes No 3-4 Small 0.323
Yes No > 4 Medium 0.457
Yes Yes 0-2 Small 0.484
No Yes > 4 Small 0.490
Yes No > 4 Large 0.495
Yes Yes 3-4 Small 0.501
Yes Yes > 4 Medium 0.640
Yes Yes > 4 Large 0.674
Yes No > 4 Small 0.763
Yes Yes > 4 Small 0.872
years. Admittedly, we did not attempt to differentiate
between discharge to a rehabilitation center and a long-
term care facility. Notably, Rectenwald et al20 examined
the “long-term” outcome after TAA repair in a relatively
large group of patients from our institution and found that
only 65% of the patients were alive, living at home, and
ambulating at 1 year.
The mortality rate for RAB in the current study
exceeds the 0% to 2% reported by Chiantella and Dean21
from a collective review of RABs performed for hyperten-
sion and likewise suggests that the approach to patients
with renal artery occlusive disease needs to be reexamined.
The mortality rate must be interpreted with some caution
because most of the RABs were performed concomitant
with other aortic procedures and the indications are unde-
fined. The mortality rate for RAB alone was 4.4% and pro-
vides a better baseline for comparison. Furthermore, it has
been our anecdotal impression that an increasing percent-
age of renal revascularizations are performed for renal sal-
vage rather than renovascular hypertension, and the
procedures performed for this indication are clearly asso-
ciated with an increased mortality rate.22 Appropriate
assessment of the various treatment options for renal
artery stenosis require comparison of not only the mortal-
ity rate, but also the long-term outcome measures includ-
ing vessel patency, blood pressure control, and
preservation of renal function. However, the attendant
death associated with RAB may be a significant price to
pay despite the fact that the longer-term outcome mea-
sures may be superior.21,23,24 In our current algorithm for
clinically significant renal artery stenosis we use angio-
plasty or stent as the first-line treatment with operative
revascularization reserved for lesions not amenable to the
endovascular approach or repeated failures. This approach
is supported by the excellent long-term results of angio-
plasty for medial fibrodysplastic lesions23,25,26 and the
improved outcome for atherosclerotic ostial lesions when
primary stents are combined with angioplasty.27-29 The
surprisingly low number of RAB performed as a single
procedure indirectly suggests that this algorithm may be
becoming the standard.
The observed increased mortality rate for combined
RAB and aortic reconstruction has been reported in other
series.30,31 This increased mortality rate has limited our
enthusiasm for combined procedures when the only indi-
cation for RAB is an asymptomatic stenosis despite con-
trary reports documenting the safety of the combined
procedures in this setting.32,33 Notably, in the studies doc-
umenting the increased mortality rate for the combined
procedures, investigators have used the aortic procedure
alone as the baseline for comparison rather than the RAB
alone. In a recent publication from our group in which we
examined the outcome after intact abdominal aortic
aneurysm repair across the United States using the same
database, a 4.2% mortality rate was reported, which is
roughly half of the mortality rate of the combined proce-
dures in the current study.3 Natural history studies with
the use of both arteriography34 and duplex ultrasound35
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have suggested that some of these asymptomatic renal
artery lesions are preocclusive. However, a recent analysis
of patients with asymptomatic renal artery stenoses who
underwent aortic reconstruction alone found that the nat-
ural history of the untreated renal artery lesions was fairly
benign and associated only with an increase in the number
of antihypertensive medications.36
The mortality rate after operative revascularization for
CMI reported in the current study is within the range of
several single institutional series.37-40 Unlike a TAA,
untreated CMI is almost uniformly fatal, with death
resulting from inanition or bowel infarction, and the
major clinical decision is not whether to treat, but rather
the specific type of treatment. The options include either
endovascular or surgical revascularization, and there are
multiple options among the latter approach. The outcome
after endovascular revascularization remains poorly
defined because of the limited experience nationwide. In a
recent collective review, Kasirajan et al41 reported a mean
4% mean operative mortality rate, an 18% mean complica-
tion rate, and a 91% mean technical success rate from
seven institutional series encompassing 122 patients.
However, the long-term outcome measures after endovas-
cular revascularization, including pain relief, ability to gain
weight, and vessel patency, remain unresolved. All of these
outcome measures have been reported to be quite good
after open revascularization.37-40
Despite the limitations of the database and the exper-
imental design, the mortality rates for TAA repair and
RAB across the country are greater than commonly
reported in the literature. These excess mortality rates
mandate reexamining the treatment strategies, which
potentially include concentrating the operative experience
in centers of excellence. Conversely, the nationwide mor-
tality rate for mesenteric revascularization for CMI is
within the range of the institutional series and suggests
that the standard of care is comparable.
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Dr Timothy Kresowik (Iowa City, Iowa). Tom, excellent
work. I have a couple of questions. One relates to risk adjustment.
One of the arguments that is always raised when you are talking
about institution size is that the patients are different. Whenever
you are making any kind of analysis based on claims data alone,
you are subject to the inaccuracies of claims and that has been
well documented. Have you done anything in terms of a valida-
tion sample based on actual chart review even in your institution
or perhaps other institutions in your state to see how accurate the
claims data are? The second question is, have you looked at risk
adjustment models to see if you can indeed adjust for the differ-
ence in mortalities?
Dr Thomas Huber. The simple answer to both your ques-
tions is actually no. We have not gone back and validated the
claims data. Our data are subject to the same criticisms that all
these administrative databases are subjected to. Specifically, the
mortality is probably accurate, the comorbidities are only reason-
ably accurate, and the complications are also only reasonably
accurate. We certainly would not compare this with a prospective
trial that documented the outcomes more appropriately.
As far as risk adjustment, we have not performed any valida-
tion. There are no good comorbidity indices in the database that
we used.
Dr James McKinsey (Chicago, Ill). I too enjoyed your talk,
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and I also share some of the concerns about the risk assessment.
Also, I raise the question of volume. Have you stratified not nec-
essarily between large institutions and urban but by centers’ total
number of cases for the disease process you are studying? A large
center may not have any experience in thoracoabdominal and a
smaller center may. The other issue is the term bad outcome being
classified for transfer to another facility. Changes in health care are
actually looking to fast track a lot of patients after their acute care
to a rehab facility, which does not necessarily mean that they are
there for a long period of time or had a bad outcome; it is just the
way the politics of medicine is now being done. Have you looked
at the type of discharge facility they are going to, or just if they
happen to go to rehab then they are counted as a bad outcome?
Dr Huber. Let me answer your second question first. Bad
outcome, which throughout the text we put in quotation marks,
is a fairly arbitrarily defined bad outcome. Although we have
actually used before, it is not ideal. The database that we used
did not allow us to track patients longitudinally, so I cannot tell
you once they are discharged to another institution where they
ultimately go. Using thoracoabdominals, we have actually
looked at our own institution, something that we will present at
the annual meeting of Southern Association for Vascular
Surgery in the next couple of months. It turns out that 65% of
the patients are home alive at a year, so I readily admit that some
patients go into a rehab center for a short period of time and
then ultimately go home. This is a lot different than going to an
extended care facility or a chronic ventilatory unit. No doubt
about it. A bad outcome is probably not quite that bad because
a significant portion of those patients discharged to a rehab cen-
ter probably get home.
As far as volume at centers, we actually did not stratify it by
institution. This database is supposedly a 20% stratified sample
across the country. The hospitals are selected to reflect the coun-
try as a whole. These procedures are very infrequent. In 6 years
we only came up with 2000 renals and 500 thoracoabdominals,
so it is difficult to look at the volume per center. I anticipated
someone would ask me whether we included the University of
Wisconsin, Baylor University, or Massachusetts General.
However, I cannot tell you whether those hospitals are included
because the data are not broken by individual hospitals.
Dr James Stanley (Ann Arbor, Mich). This is very important
work. However, it may be taken out of context by others, particu-
larly payers. For instance your data might support routine endovas-
cular therapy for renal artery occlusive disease rather than a bypass
or endarterectomy. In an aggregate national experience that may be
true, but in specific cases it may not reflect acceptable contempo-
rary practice. The mortality that you have reported is quite similar
to the unacceptable mortality from the only benchmark experience
involving renovascular disease, namely, the Cooperative Study on
Renovascular Hypertension, published in a series of JAMA papers
nearly a quarter of a century ago. At that time considerable concern
existed regarding operative deaths, and one would have to have the
same concern about the data you presented. If everyone had these
outcomes a very different referral pattern and payer practice would
exist for the treatment of renovascular disease. Outcomes are
exceedingly important and from my perspective must be based on
the practices of an institution or individual practitioner. To assign
importance to large clinical databases without a caveat recognizing
the relevance of hospital volume or an individual surgeon’s practice
is hazardous. Outcome studies that have changed the way surgical
care is provided to a population have usually involved a hands-on
review of data from specific patients and careful substratification of
operative risks. Simple matter such as whether endarterectomy or
bypass were included in the reconstructive category for renal artery
surgery in this database, and the issue of preoperative renal failure
as a comorbidity might make interpretation of this information
quite different.
Dr Huber. I would say I support all your concerns regarding
interpreting the data. We found an 8% mortality rate for those
bypasses done in conjunction with aortic procedure, which breaks
down to 7% overall and 4% when the renal artery bypass is done
alone. The conclusions for the thoracoabdominal apply to what
we see with renal artery bypasses. I think everyone needs to look
at their own outcomes, and if your mortality rate is excessive then
one needs to redefine the indications or identify a surgeon, a
group of surgeons, or a select center that has better outcomes.
This is what we found across the country but I second all your
concerns about the bench-marking.
We only used codes for aortorenal bypass, so what we are
missing is endarterectomies and extra-anatomic bypasses. It turns
out that the diagnostic code for renal artery bypasses or aortore-
nal bypasses is very specific. ICD-9 diagnostic codes for those
other procedures are very vague and include a whole bunch of
other procedures.
Dr Charles Acher (Madison, Wis). I enjoyed your paper. I
think it points out some important things. The comments that
were already made clearly point to some of the problems with
using this to interpret individual experiences, but the thing I was
curious about in your—you left out acuity as really a stratifying
thing in your thoracoabdominal search. I do not know if that is
available in the database, but depending on the institution as high
as 30% or 40% of the patients who present may present with acute
dissection, rupture, or contained rupture and of course the out-
comes in those patients are going to be significantly different than
in elective patients, and in fact at our own institution 80% of our
mortalities are in the acute patients with the elective mortality
being under 4%, so were you able to look at that?
Dr Huber. That is the easiest question I have gotten. The codes
that we used use intact thoracoabdominal aneurysms, so we specif-
ically excluded any ruptures. There are some potentially emergent
admissions, but they are all intact nonruptured aneurysms.
Dr John Corson (Iowa City, Iowa). As you well know there
are various types of thoracoabdominal aneurysms that have dif-
ferent anticipated outcomes. How many of these cases were type
I or II thoracoabdominal aneurysms? I think your data could be
misused unless you can identify the outcome for each type of tho-
racoabdominal aortic aneurysm.
Dr Huber. No, actually we cannot break down the types from
our database. Granted there is some difference in the mortality
rate by type, but these differences are not dramatic.
